← Browse by Condition
Medical Condition

pmmr mss adenocarcinoma of the colon or rectum

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for pmmr mss adenocarcinoma of the colon or rectum sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — pmmr mss adenocarcinoma of the colon or rectum Clinical Trials

How many clinical trials are currently recruiting for pmmr mss adenocarcinoma of the colon or rectum?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for pmmr mss adenocarcinoma of the colon or rectum, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for pmmr mss adenocarcinoma of the colon or rectum?
pmmr mss adenocarcinoma of the colon or rectum research spans Phase 1 (2 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a pmmr mss adenocarcinoma of the colon or rectum clinical trial?
Eligibility criteria for pmmr mss adenocarcinoma of the colon or rectum trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
2
Top Sponsors
GV20 Therapeutics 2 trials

Recruiting Clinical Trials

NCT05669430 Phase 1, Phase 2
Recruiting
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Enrollment
365 pts
Location
United States
Sponsor
GV20 Therapeutics
View Trial →
NCT07070518 Phase 1, Phase 2
Recruiting
Study of GV20-0251 in Participants With Solid Tumor Malignancies
Enrollment
350 pts
Location
China
Sponsor
GV20 Therapeutics
View Trial →

Related Conditions

endometrial carcinoma ec (2) squamous head and neck carcinoma (2) non small cell lung cancer (2) solid tumor adult (1) refractory cancer (1) cutaneous melanoma (1) solid tumor cancer (1) adult refractory cancer (1) melanoma (1) hcc hepatocellular carcinoma (1) small cell lung cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology